Monitoring in metastatic breast cancer: Is imaging outdated in the era of circulating tumor cells?

Breast Care

Volumn 9, Issue 1, 2014, Pages 16-21

  Alunni Fabbroni, Marianna ^a   Müller, Volkmar ^b   Fehm, Tanja ^c   Janni, Wolfgang ^d   Rack, Brigitte ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Breast cancer; Circulating tumor cells; Imaging; Metastatic breast cancer; Minimal residual disease; MRI; PET CT

Indexed keywords

BREAST METASTASIS; CANCER PROGNOSIS; CANCER REGRESSION; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MEDICAL DECISION MAKING; PREDICTIVE VALUE; REMISSION; RISK FACTOR;

EID: 84897061970     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000360438     Document Type: Review

References (66)

1. Glendenning J, Cook G: Imaging breast cancer bone metastases: Current status and future directions. Semin Nucl Med 2013;43:317-323.
2. Ferlay J, Shin HR, Bray F, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3. Sree SV, Ng EY, Acharya RU, Faust O: Breast imaging: A survey. World J Clin Oncol 2011;2:171-178.
4. Hall FM: Transition to digital mammography. Radiology 2012;262:374.
5. De Abreu FB, Wells WA, Tsongalis GJ: The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. Am J Pathol 2013;183:1075-1083.
6. Jalalian A, Mashohor SB, Mahmud HR, et al.: Computer-aided detection/diagnosis of breast cancer in mammography and ultrasound: A review. Clin Imaging 2013;37:420-426.
7. Cote RJ, Rosen PP, Lesser ML, et al.: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-1756.
8. Diel IJ, Kaufmann M, Costa SD, et al.: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88:1652-1658.
9. Wei S, Li Y, Siegal GP, Hameed O: Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. Ann Diagn Pathol 2011;15:79-83.
10. Jung SY, Rosenzweig M, Sereika SM, et al.: Factors associated with mortality after breast cancer metastasis. Cancer Causes Control 2012; 23:103-112.
11. Manders K, van de Poll-Franse LV, Creemers GJ, et al.: Clinical management of women with metastatic breast cancer: A descriptive study according to age group. BMC Cancer 2006;6:179.
12. Tateishi U, Gamez C, Dawood S, et al.: Bone metastases in patients with metastatic breast cancer: Morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008;247:189-196.
13. Grizzle WE, Srivastava S, Manne U: Translational pathology of neoplasia. Cancer Biomark 2010;9:7-20.
14. Fass L: Imaging and cancer: A review. Mol Oncol 2008;2:115-152.
15. Alix-Panabieres C, Pantel K: Circulating tumor cells: Liquid biopsy of cancer. Clin Chem 2013;59: 110-118.
16. Alix-Panabieres C, Schwarzenbach H, Pantel K: Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012;63:199-215.
17. Lin NU, Thomssen C, Cardoso F, et al.: International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013;22:203-210.
18. Cardoso F, Harbeck N, Fallowfield L, et al.: Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii11-9.
19. Duffy MJ: Serum tumor markers in breast cancer: Are they of clinical value? Clin Chem 2006;52:345-351.
20. Dose Schwarz J, Bader M, Jenicke L, et al.: Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144-1150.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
23. Lagalla R, Caruso G, Finazzo M: Monitoring treatment response with color and power Doppler. Eur J Radiol 1998;Suppl 2:S149-156.
24. Westwood M, Joore M, Grutters J, et al.: Contrastenhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast- enhanced computed tomography and contrast- enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: A systematic review and costeffectiveness analysis. Health Technol Assess 2013;17:1-243.
25. Guang Y, Xie L, Ding H, et al.: Diagnosis value of focal liver lesions with SonoVue®-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: A metaanalysis. Cancer Res Clin Oncol 2011;137:1595-1605.
26. Yu JQ, Cristofanilli M: Circulating tumor cells and PET. J Nucl Med 2011;52:1501-1504.
27. Bos R, van Der Hoeven JJ, van Der Wall E, et al.: Biologic correlates of (18F)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-387.
28. Kilburn-Toppin F, Barter SJ: New horizons in breast imaging. Clin Oncol (R Coll Radiol) 2013; 25:93-100.
29. Rose C, Dose J, Avril N: Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun 2002;23:613-618.
30. Rohren EM, Turkington TG, Coleman RE: Clinical applications of PET in oncology. Radiology 2004;231:305-332.
31. Cohade C: Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect. Semin Nucl Med 2010;40:283-293.
32. Braun S, Pantel K, Müller P, et al.: Cytokeratinpositive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-533.
33. Schindlbeck C, Pfab G, Jueckstock J, et al.: Prognostic relevance of disseminated tumor cells in the bone marrow of patients with primary breast cancer - results of a standardized follow-up. Anticancer Res 2011;31:2749-2755.
34. Schindlbeck C, Andergassen U, Hofmann S, et al.: Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. J Cancer Res Clin Oncol 2013;139:1055-1062.
35. Pantel K, Alix-Panabieres C, Riethdorf S: Cancer micrometastases. Nat Rev Clin Oncol 2009;6:339-351.
36. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-846.
37. Kim MY, Oskarsson T, Acharyya S, et al.: Tumor self-seeding by circulating cancer cells. Cell 2009; 139:1315-1326.
38. Aguirre-Ghiso JA: On the theory of tumor selfseeding: Implications for metastasis progression in humans. Breast Cancer Res 2010;12:304.
39. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-445.
40. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, et al.: Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse. Clin Exp Metastasis 2008;25:871-875.
41. Janni W, Gastroph S, Hepp F, et al.: Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer 2000;88:2252-2259.
42. Osta WA, Chen Y, Mikhitarian K, et al.: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-5824.
43. Gorges TM, Pantel K: Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother 2013;62:931-939.
44. Riethdorf S, Fritsche H, Müller V, et al.: Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin Cancer Res 2007;13:920-928.
45. Cristofanilli M, Budd GT, Ellis MJ, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351: 781-791.
46. Aktas B, Müller V, Tewes M, et al.: Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011; 122:356-360.
47. Giordano A, Gao H, Anfossi S, et al.: Epithelialmesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 2012;11:2526-2534.
48. Wallwiener M, Hartkopf AD, Baccelli I, et al.: The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013;137:503-510.
49. Pierga JY, Hajage D, Bachelot T, et al.: High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23:618-624.
50. Cristofanilli M, Hayes DF, Budd GT, et al.: Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-1430.
51. Hayes DF, Cristofanilli M, Budd GT, et al.: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218-4224.
52. Nole F, Munzone E, Zorzino L, et al.: Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008;19:891-897.
53. Janni W, Rack B, Terstappen L, et al.: A pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer, San Antonio Breast Cancer Symposium 2013 (San Antonio, TX, USA).
54. Dawood S, Broglio K, Valero V, et al.: Circulating tumor cells in metastatic breast cancer: From prognostic stratification to modification of the staging system? Cancer 2008;113:2422-2430.
55. Müller V, Riethdorf S, Rack B, et al.: Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: The DETECT study. Breast Cancer Res 2012;14:R118.
56. Nakamura S, Yagata H, Ohno S, et al.: Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010;17:199-204.
57. Jiang ZF, Cristofanilli M, Shao ZM, et al.: Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): A multicenter, double-blind, prospective trial. Ann Oncol 2013;24:2766-2772.
58. Bidard FC, Fehm T, Ignatiadis M, et al.: Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013;32:179-188.
59. Bidard F-C, Peeters D, Fehm T, et al.: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data. San Antonio Breast Cancer Symposium 2013 (San Antonio, TX, USA).
60. Rack B, Schindlbeck C, Schneeweiss A, et al.: Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy - The German SUCCESS-Trial. J Clin Oncol (Meeting Abstracts) 2008;26 Suppl:503.
61. Budd GT, Cristofanilli M, Ellis MJ, et al.: Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-6409.
62. De Giorgi U, Valero V, Rohren E, et al.: Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009;27:3303-3311.
63. Liu MC, Shields PG, Warren RD, et al.: Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27:5153-5159.
64. De Giorgi U, Valero V, Rohren E, et al.: Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 2010;21:33-39.
65. De Giorgi U, Mego M, Rohren EM, et al.: 18FFDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 2010;51:1213-1218.
66. Smerage JB, Barlow WE, Hayes DF, et al.: SWOG S0500 - A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. San Antonio Breast Cancer Symposium 2013 (San Antonio, TX, USA).